Radiopharm Theranostics (Radiopharm Theranostics) Ending Cash Position : $1.27 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Ending Cash Position?

Radiopharm Theranostics's Ending Cash Position for the quarter that ended in Dec. 2023 was $1.27 Mil.

Radiopharm Theranostics's quarterly Ending Cash Position declined from Dec. 2022 ($16.36 Mil) to Jun. 2023 ($7.85 Mil) and declined from Jun. 2023 ($7.85 Mil) to Dec. 2023 ($1.27 Mil).

Radiopharm Theranostics's annual Ending Cash Position increased from . 20 ($0.00 Mil) to Jun. 2022 ($18.96 Mil) but then declined from Jun. 2022 ($18.96 Mil) to Jun. 2023 ($7.85 Mil).

Radiopharm Theranostics Ending Cash Position Historical Data

The historical data trend for Radiopharm Theranostics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Ending Cash Position Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Ending Cash Position

18.96

7.85

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	23.31	18.96	16.36	7.85	1.27

Radiopharm Theranostics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Radiopharm Theranostics's Ending Cash Position for the fiscal year that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	18.107	+	-10.255
	=	7.85

Radiopharm Theranostics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	7.831	+	-6.563
	=	1.27

Radiopharm Theranostics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

RAD:Australia

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-10-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-20-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 07-10-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire • 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-30-2022

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

By PRNewswire PRNewswire • 08-04-2022